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Abstract 
Objective: To compare the quality and acceptability of a new headache-specific patient-reported measure, the Chronic 
Headache Quality of Life Questionnaire (CHQLQ) with the six-item Headache Impact Test (HIT-6), in people meeting 
an epidemiological definition of chronic headaches. 
Methods: Participants in the feasibility stage of the Chronic Headache Education and Self-management Study (CHESS) 
(n ¼ 130) completed measures three times during a 12-week prospective cohort study. Data quality, measurement 
acceptability, reliability, validity, responsiveness to change, and score interpretation were determined. Semi-structured 
cognitive interviews explored measurement relevance, acceptability, clarity, and comprehensiveness. 
Results: Both measures were well completed with few missing items. The CHQLQ’s inclusion of emotional wellbeing 
items increased its relevance to participant’s experience of chronic headache. End effects were present at item level only 
for both measures. Structural assessment supported the three and one-factor solutions of the CHQLQ and HIT-6, 
respectively. Both the CHQLQ (range 0.87 to 0.94) and HIT-6 (0.90) were internally consistent, with acceptable tem-
poral stability over 2 weeks (CHQLQ range 0.74 to 0.80; HIT-6 0.86). Both measures responded to change in headache-
specific health at 12 weeks (CHQLQ smallest detectable change (improvement) range 3 to 5; HIT-6 2.1). 
Conclusions: While both measures are structurally valid, internally consistent, temporally stable, and responsive to 
change, the CHQLQ has greater relevance to the patient experience of chronic headache. 
Trial registration number: ISRCTN79708100. Registered 16th December 2015, http://www.isrctn.com/ 
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Introduction 
Chronic headaches, which can be defined epidemiolog-
ically as headaches on 15 or more days per month for 
at least 3 months (1–3), have profound effects on peo-
ple’s lives. Those affected describe strained relation-
ships, and that the spectre of headaches can be a 
crucial driver of their behaviour (4). When testing 
treatments for these chronic headache disorders, an 
international, multi-stakeholder consensus process 
rated the measurement of the overall health impact of 
chronic headaches as being at least as important as 
counting headache days (5). These health impacts 
should be assessed using patient-reported outcome 
measures (PROMs) with robust evidence of measure-
ment quality, relevance, and acceptability (5,6). There 
is substantial heterogeneity in PROMS used in trials of 
headache disorders (7). 
A 2018 systematic review of PROMS for headaches 
found the strongest, albeit limited, evidence was for 
two headache-specific measures (7), the Migraine-
Specific Questionnaire (MSQ v2.1) (8) and the six-
item Headache Impact Test (HIT-6) (9). However, 
essential evidence of data quality and interpretation, 
reliability, and responsiveness was mostly absent or 
of insufficient quality. Moreover, the relevance and 
acceptability of these measures to people with headache 
were not explored. The use of PROMs that lack rele-
vance to patients, and hence fail to capture the out-
comes that matter, places an unnecessary burden on 
patients, and maybe judged to be unethical (10). 
We report here on a mixed-methods comparative 
evaluation of the measurement and practical properties 
of the HIT-6 and an adaption of the MSQ v2.1 to make 
it suitable for people with unspecified chronic headache 
disorders – the Chronic Headache Quality of Life 
Questionnaire (CHQLQv1.0). 
Methods 
The Chronic Headache Education and Self-
Management Study (CHESS) is a programme grant 
funded by the UK’s National Institute for Health 
Research (RP-PG-1212-20018) to test the effectiveness 
of a supportive self-management intervention for 
people living with chronic headache disorders (11). 
This current work forms part of the feasibility study, 
reported elsewhere (January 2016 to April 2017) (Black 
Country Research Ethics Committee (15/WM/0165)) 
(12). In summary, participants completed question-
naires on three occasions during a 12-week prospective 
cohort study (baseline, 2 and 12 weeks). 
Study population 
We recruited people living with chronic headaches, pre-
dominantly chronic migraine or chronic tension-type 
headache, from general practices in the West 
Midlands region of the UK. Practices wrote to people 
who had, in the previous 2 years, consulted for head-
aches or had a prescription for a migraine-specific drug 
(i.e. triptans/pizotifen), inviting expression of interest 
in the study. In a subsequent telephone interview, 
study team members assessed if participants met an 
epidemiological definition of chronic headaches: 
Headache for 15 or more days per month for at least 
3 months (1–3). For this validation of a generic 
headache-related quality of life outcome that is not 
diagnosis specific, this is the appropriate population. 
However, as part of this overall programme of work, 
we also validated a classification interview in this pop-
ulation. Of the 131 people included in this report, 107 
(82%) also had paired telephone interviews with 
research nurses and doctors from the National 
Migraine Centre. The final classification was: Definite 
chronic migraine (59; 55%), probable chronic migraine 
(40; 37%) chronic tension-type headache (6; 6%), clus-
ter headache (2; 2%), hemicrania continua (1; 1%). 
Over half, 44/74 (59%), also had medication overuse 
defined as “headache occurring on 15 or more days per 
month taking acute or symptomatic headache medica-
tion (on 10/15 or more days per month, depending on 
the medication) for more than 3 months”. The sample 
size was driven by requirements for validation of a 
chronic headache classification interview. This work 
is described in detail elsewhere (13). 
Patient-reported outcome measures 
The feasibility study included general headache-specific 
(not diagnosis-specific), generic and domain-specific 
measures and a headache-specific health transition 
question (detailed in Appendix 1). The CHQLQ is a 
14-item questionnaire, which assesses the functional 
aspects of headache-related quality of life, producing 
three domain scores (role prevention, role restriction, 
and emotional function) (8). Modification of the 
CHQLQ from the MSQ (v2.1) simply involved replac-
ing the word ‘migraines’ with ‘headaches’ throughout 
the questionnaire. The HIT-6 is a 6-item questionnaire, 
which produces a single index score of headache impact 
on functional ability (9). Participants self-completed 
postal questionnaires at baseline, 2 and 12 weeks. 
Analysis 
Psychometric properties of the measures were com-
pared ((14,15); Appendix 2). 
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Data quality and interpretability. Item-scale characteristics, 
completion rates (missing data) and percentage of com-
putable scale scores are reported (15,16). 
Interpretability was informed by evidence of end effects 
and calculation of the minimal important change 
(MIC) – the smallest change in score perceived as 
important by participants) (15) – calculated as the 
mean change score for people reporting “minimal 
change” in their headache at 12 weeks. 
Structural validity and internal consistency. An exploratory 
factor analysis on baseline data hypothesised that the 
CHQLQ’s original three-factor solution would be 
retained. Absolute item loadings 0.45 were accepted 
as sufficient correlation with a principal component to 
support domain inclusion. Confirmatory factor analy-
sis was then used to confirm the three- and one-factor 
structures of the CHQLQ and HIT-6, respectively. 
Factor loadings exceeding 0.3–0.4 were judged to be 
meaningful (15–17). Internal consistency was assessed 
with Cronbach’s alpha (15,16) values between 0.7 and 
0.90 suggest a good to excellent agreement between 
items and the total (domain) score (15,16). 
Reliability and measurement error. Two-week test-retest 
reliability (intra-class correlation coefficient (ICC 2,1)) 
was assessed in those indicating no change in their head-
ache. We calculated the standard error of measurement 
(SEM) to determine the extent of absolute measurement 
error (6,18,19). The SEM supports score interpretation 
by accounting for variability, or error, in measurement – 
only a change greater than measurement error is consid-
ered ‘real’ (18). The SEM was subsequently converted 
into the smallest detectable change (SDC), representing 
the smallest change in score that is greater than mea-
surement error; the SDC was calculated for individuals 
and for groups (19,20). The SDC allows one to rule out 
measurement error (i.e. distinguishing measurement 
error from true change) when assessing the reliability 
of a self-reported measure to detect change in health 
status. Thus, a score change greater than the SDC 
value is necessary to provide evidence of true change 
(improvement or deterioration) in health-status. 
Construct validity. Score correlation between measures 
was assessed to evaluate convergent validity (Pearson’s 
correlation coefficient). Hypothesised theoretical associ-
ations were considered a priori  (Appendix 2). 
Responsiveness. Responsiveness reflects the ability of a 
measure to detect real change in health that is greater 
than measurement error. 
(i) Smallest detectable change (SDC) 
We calculated the absolute measurement error at 12 
weeks (standard error of measurement (SEM) and the 
smallest detectable change (SDC)), to represent the 
smallest change in score that is greater than measure-
ment error in patients reporting change in headache at 
12 weeks. We calculated the minimal important change 
(MIC) as the mean change in those reporting minimal 
improvement or deterioration at 12 weeks. We calcu-
lated the minimal important clinical difference (MICD) 
as the mean change in score in those who are 
“somewhat better” minus the mean change in those 
who are the same at 12 weeks (6,16). 
(ii) Criterion-based assessment 
Receiver operating characteristic (ROC) curves were 
calculated to assess the ability of measures to discrim-
inate between people whose headache had improved or 
deteriorated (on headache-specific transition question) 
at 12 weeks (16). An area under the curve (AUC) score 
of > 0.70 is considered sufficiently discriminatory; an 
AUC of 0.5 suggests no discriminatory power. 
(iii) Effect size (ES) and standardized response mean 
(SRM) 
The ES and SRM were calculated for subgroups of 
patients in each health transition category. The main 
hypotheses we tested were: ES and SRM would be <0.2 
for patients who reported no change in headache; >0.2 
for patients reporting a slight improvement; >0.5 for 
patients reporting improvement (much better); greater 
for patients indicating an improvement in their head-
ache than those indicating no change. 
Content validity 
Semi-structured cognitive interviews were conducted 
within 24 h of questionnaire self-completion with a pur-
posive sample (age, gender, headache type) of partici-
pants. Measurement relevance, acceptability, clarity, 
and comprehensiveness were explored (21,22). 
Overarching questions explored how patients deter-
mined headache improvement, and if specific questions 
were missing. Interviews continued until thematic satu-
ration was achieved; they were audio-recorded, tran-
scribed verbatim, and checked for accuracy (VN). We 
used framework analysis (23) and cross-case compari-
son to generate themes. NVivo software (QSR 
International Pty Ltd. Version 11, 2015) supported 
data organisation. Data were independently explored 
by two researchers (VN, KH); emergent themes were 
discussed and interpreted with a third researcher (FG) 
and with two of our patient research partners (BB, LM). 
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Results 
We recruited 131 people: 130, 115 (88%) and 103 
(79%) questionnaires were completed at baseline, 2 
and 12 weeks, respectively (Table 1) (11). 
Data quality and interpretability 
Item missing data for the CHQLQ was low (range 0% 
to 3%); domain scores were computable for 96% (role 
prevention), 97% (role restriction) and 100% (emo-
tional function) of respondents (Table 2). All response 
Table 1. Patient characteristics at baseline and follow-up. 
options were endorsed. Except item 12 (“fed up or 
frustrated”), which correlated more highly with role 
restriction (0.71) than emotional function domain 
(0.64), all item-total correlations with specified 
domains were greater than 0.7 (Table 3). 
There were no missing data for the HIT-6; index 
scores were computable for all responders. Except for 
item 1 (pain severity), for which response option 1 
(“never”) was not endorsed, all response options were 
supported. Item-total correlations ranged from 0.68 to 
0.79, with five of the six items achieving scores higher 
than 0.70 (Table 3). 
Baseline (n ¼ 130) 2-week response (n ¼ 115) 12-week response (n ¼ 103) 
Characteristic n (%) n (%) p-value1 n (%) p-value1 
Age (years) 
Mean (SD) 48.7 (13.2) 49.8 (13.1) 0.006 49.8 (13.1) 0.006 
Range 21–77 21–77 21–77 
Gender 0.447 
Female 107 (82.3%) 93 (81%) 0.483 84 (82%) 
Unknown 2 (1.5%) 2 (2%) – 1 (1%) 
Ethnicity 0.004 
White 124 (95.4%) 112 (97%) 0.002 101 (98%) 
Non-white 5 (3.8%) 2 (2%) 0.002 1 (1%) 
Not reported 1 (0.8%) 1 (1%) – 1 (1%) 
Left school at 0.46 
Age 13–16 35 (26.9%) 33 (29%) 0.085 29 (28%) 
Age 17–19 47 (36.2%) 41 (36%) 0.085 37 (36%) 
Age 20 or over 43 (33.1%) 37 (32%) 0.085 34 (33%) 
In full-time education 3 (2.3%) 3 (3%) 2 (2%) 
Other 1 (0.8%) 0 – – 
Not reported 1 (0.8%) 1 (1%) – 1(1%) 
Employment status 0.487 
Employed 85 (65.4%) 73 (63%) 0.724 65 (63%) 
Retired from paid work 22 (16.9%) 21 (18%) 0.724 20 (19%) 
At school or in full time education 2 (1.5%) 2 (2%) – 2 (2%) 
Looking after your home/family 11 (8.5%) 9 (8%) 0.724 8 (8%) 
Unable to work due to long term sickness 3 (2.3%) 3 (3%) – 3 (3%) 
Other 2 (1.5%) 2 (2%) – 2 (2%) 
Not reported 5 (3.8%) 5 (4%) – 3 (3%) 
Type of headache 
Definite chronic migraine 59 (45.4%) 57 (50%) <0.001 48 (47%) <0.001 
Probable chronic migraine 40 (30.8%) 37 (32%) 37 (36%) 
Chronic tension 6 (4.6%) 5 (4%) 6 (6%) 
Unknown 25 (19.2%) 16 (14%) 12 (12%) 
Medication overuse 
Yes 68 (52.3%) 66 (57%) <0.001 57 (55%) <0.001 
No 37 (28.5%) 33 (29%) 34 (33%) 
Unknown 25 (19.2%) 16 (14%) 12 (12%) 
1p-values compare baseline characteristics of responders and non-responders at the 2-week and 12-week follow-up assessment point. 
66 (57%) <0.001 57 (55%) <0.001 
33 (29%) 34 (33%) 
16 (14%) 12 (12%) 
 
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Table 2. Item and scale properties of the CHQLQ and HIT-6 at baseline (n ¼ 130). 
Response optionsc 
% Floor % Ceiling 
Percentage Minimum Maximum (minimum (maximum 
missing Mean (SD) score score Median score) score) 
Headache-specific 
CHQLQa 
Items (score range 1–6) 
Role function – Restrictive (RR) 
1. Interfered with family 1.00 3.17 1.26 1 6 3 8.5% 5.4% 
2. Interfered with leisure 1.00 3.27 1.20 1 6 3 5.4% 4.6% 
3. Difficulty doing work 1.00 3.10 1.12 1 6 3 6.9% 0.8% 
4. Getting work done 1.00 3.23 1.08 1 6 3 4.6% 2.3% 
5. Limit work concentration 2.00 3.27 1.13 1 6 3 4.6% 0.8% 
6. Left too tired 1.00 3.24 1.28 1 6 3 7.7% 3.8% 
7. Limited energetic days 1.00 3.46 1.26 1 6 3 3.8% 5.4% 
Role function – Prevention (RP) 
8. Had to cancel work 2.00 2.30 1.13 1 6 2 25.4% 1.5% 
9. Needed help doing routine tasks 3.00 2.16 1.22 1 6 2 37.7% 1.5% 
10. Stop work or daily activities 2.65 1.16 1 6 2 13.8% 1.5% 
11. Not able to go to social activities 2.00 2.23 1.19 1 6 2 30.0% 0.8% 
Emotional Function (EF) 
12. Often felt fed up or frustrated 0.00 3.88 1.34 1 6 4 2.3% 12.3% 
13. Often felt like a burden 0.00 2.72 1.63 1 6 2 33.1% 7.7% 
14. Often been afraid of letting 0.00 2.95 1.65 1 6 3 23.8% 11.5% 
others down 
Domain scores (0–100) 
Role restriction (RR) 3.00 54.21 17.08 17 90 52 0.0% 0.0% 
(items 1–7) (n ¼ 124) 
Role prevention (RP) 4.00 39.01 16.89 17 100 35.5 0.0% 0.8% 
(items 8–11) (n ¼ 124) 
Emotional function (EF) 0.00 52.99 22.84 17 100 50 0.0% 3.8% 
(items 12–14) (n ¼ 124) 
HIT-6 
Items (score range 1–5) 
1. How often is pain severe 0.00 3.63 0.74 2 5 4 0.00% 10.00% 
2. Limit usual daily activities 0.00 3.25 0.85 1 5 3 3.10% 4.60% 
3. Lie down 0.00 3.69 1.08 1 5 4 5.40% 24.60% 
4. Felt too tired to do work or 0.00 3.16 0.87 1 5 3 5.40% 3.10% 
daily activities 
5. Felt fed up or irritated 0.00 3.62 0.94 1 5 4 1.50% 17.70% 
6. Limit ability to concentrate on work 0.00 3.38 0.85 1 5 3 2.30% 7.70% 
Index score (0–100) 
HIT-6 (n ¼ 130)b 0.00 62.51 6.91 38 78 63 0.00% 1.50% 
aCHQLQ: Each item has six descriptive response options, ranging from ‘None of the time’ (1 point) to ‘All of the time’ (6 points). Three domain scores: 
Role function – restrictive (RR); Role function – preventative (RP); and Emotional function (EF) – are calculated as the sum of item responses across 
each domain, rescaled to a 0–100 scale, where the higher score indicates better headache-related quality of life. A floor effect at item level is where 
more than 15% of responders score at the minimum (floor) indicating “best” health on the CHQLQ. 
bHIT-6: Each item has five descriptive response options, with each awarded a specific number of points: “Never” (6 points), “Rarely” (8 points), 
“Sometimes” (10 points), “Very often” (11 points) and “Always” (13 points). The score is the sum of item (points) responses. The index score ranges 
from 36 to 78, where scores 49 indicate little to no impact on life; 50–55 indicates some impact on life; 56–59 indicates substantial impact on life; and 
60 indicates very severe impact on life. A floor effect at item level is where more than 15% of responders score at the minimum (floor) indicating 
“best” health on the HIT-6. 
cEnd effects: Where more than 15% of respondents score the minimum (floor) or maximum (ceiling) score respectively. 
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Table 3. Exploratory (EFA) and confirmatory (CFA) factor analysis: Standardised factor loadings for the proposed three-factor 
measurement model for the CHQLQ and single-factor measurement model of the HIT-6. 
Structural validity Internal consistency 
Cronbach’s 
EFA CFA cITCa alpha 
Eigenvalues >1.0 
Headache-specific RR RP EF RR RP EF 
Proportion variance 0.30 0.20 0.20 
Proportion variance explained 0.43 0.29 0.28 
CHQLQ 
Role function – restrictive (RR) 0.94 
1. Interfered with family 0.59 0.47 0.80 0.76 0.67 0.7 – 
2. Interfered with Leisure 0.71 0.85 0.83 0.72 0.62 – 
3. Difficulty doing work 0.71 0.89 0.85 0.74 0.69 – 
4. Getting work done 0.71 0.41 0.86 0.83 0.72 0.6 – 
5. Limit work concentration 0.63 0.41 0.78 0.75 0.67 0.59 – 
6. Left too tired 0.65 0.42 0.85 0.82 0.75 0.65 – 
7. Limited energetic days 0.71 0.80 0.79 0.65 0.55 – 
Role function – preventative (RP) 0.89 
8. Had to cancel work 0.40 0.70 0.83 0.72 0.77 0.58 – 
9. Needed help doing routine tasks 0.46 0.54 0.78 0.69 0.72 0.65 – 
10. Stopped work or daily activities 0.44 0.64 0.81 0.71 0.76 0.54 – 
11. Not able to go to social activities 0.65 0.81 0.7 0.75 0.6 – 
Emotional function (EF) 0.87 
12. Often felt fed up or frustrated 0.46 0.48 0.71 0.71 0.62 0.64 – 
13. Often felt like a burden 0.86 0.93 0.67 0.65 0.84 – 
14. Often been afraid of letting others down 0.80 0.86 0.61 0.57 0.78 – 
Assessment of model fit:b 
Chi-square p-value (DF) <0.001 (74) 
CFI/TLI 0.95 0.95/0.94 
RMSEA (90% confidence interval) 0.079 (0.05, 0.09) 0.086 (0.06, 0.11) 
RMSR 0.03 0.06 
HIT-6 (index score) – 0.90 
1. How often is pain severe 0.71 0.68 – 
2. Limit usual daily activities 0.85 0.79 – 
3. Lie down 0.80 0.75 – 
4. Felt too tired to do work or daily activities 0.85 0.79 – 
5. Felt fed up or irritated 0.74 0.72 – 
6. Limit ability to concentrate on work 0.78 0.75 – 
Assessment of model fit:b 
Chi-square (DF) 0.013 (9) 
CFI/TLI 0.974/0.957 
RMSEA (90% confidence interval) 0.101 (0.044, 0.158) 
acITC: Corrected Item-Total Correlations (the extent to which items are adequate reflections of the underlying construct (12,13). 
bCFA model fit was examined using Comparative Fit Index (CFI), Tucker-Lewis Index (TLI), and the Root Mean Square Error of Approximation 
(RMSEA). 
Note: Values in bold represent corrected item-total correlations between items and their respective total domain scores. 
down” or feel “fed up or irritated” when experiencing 
Floor effects (>15%) were identified for three 
a headache, suggesting the importance of these items, 
CHQLQ role-prevention items and two emotional 
but further impact discrimination was impossible. 
function items, suggesting many respondents were not 
“prevented” from undertaking usual activities or expe-
Structural validity and internal consistency 
rienced specific emotional difficulties (Table 2). Ceiling 
effects were observed for two HIT-6 items: >15% Standard loadings and goodness-of-fit indices for the 
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Table 4. Two-week test-retest reliability (ICC 2,1), standard error of measurement (SEM) and smallest detectable change (SDC) for 
the CHQLQ and HIT-6. 
Baseline Re-test Changea 
SDC SDC ICC 
N Mean (SD) Mean (SD) Mean (SD) SEMb individualc d group (95% CI)e 
Headache-specific 
CHQLQ (domain scores 0–100) 
RR 67 62.16 (17.05) 67.46 (16.72) 5.30 (11.44) 8.09 22.42 2.74 0.74 (0.55, 0.84) 
RP 67 77.04 (18.00) 79.88 (16.99) 2.84 (11.96) 8.459 23.45 2.86 0.76 (0.63, 0.85) 
EF 67 63.25 (23.64) 67.04 (24.83) 3.79 (14.96) 10.576 29.32 3.58 0.80 (0.69, 0.87) 
HIT-6 (range 35–78) 73 62.56 (7.13) 61.03 (6.77) 1.53 (3.42) 2.415 6.69 0.78 0.86 (0.75, 0.92) 
aSelf-reported change in headache was captured on a headache-specific health-transition question at 2 weeks. 
bSEM: Standard Error of Measurement. 
cSDCindividual represents the SDC in individuals and is calculated as: (SEM 1.96 2) (15,16). 
dSDCgroup represents the SDC in a group of individuals and is calculated as: (1.96 2 SEM n, where n is the group size) (6,15,16). 
eICC (95% CI): Intra-class correlation coefficient (1,2) with 95% confidence intervals. 
three-factor model, with factor loadings > 0.50 for all 
items except item 12 (“fed up or frustrated”) (Table 3). 
Role restriction accounted for the majority (43%) of 
data total variance. Confirmatory factor analysis pro-
duced a good data fit, supporting the CHQLQ’s three-
domain model. Confirmatory factor analysis supported 
the HIT-6 single domain, with all component 
loadings > 0.70. Cronbach’s alpha ranged 0.87 to 0.94 
for the CHQLQ domains and 0.90 for the HIT-6, indi-
cating high internal consistency. 
Reliability 
All values for the CHQLQ and HIT-6 exceeded the 
lower threshold for acceptable test-retest reliability 
(intra-class correlation coefficient > 0.70), supporting 
use with groups of patients (Table 4). The standard 
error of measurement for the CHQLQ domains were 
8.09 (role restriction), 8.46 (role prevention) and 10.58 
(emotional function), resulting in smallest detectable 
change for individuals (SDCindividual) values of 22.42, 
23.45 and 29.32, respectively. The corresponding small-
est change in scores that can be detected at the group 
level (SDCgroup) was 2.74 (role restriction), 2.86 (role 
prevention) and 3.58 (emotional function). This implies 
that, when using the CHQLQ for individual assessment, 
changes in people with stable symptoms would need to 
be greater than 22, 24 or 29 points (between 22% and 
29% of total score change) to be distinguishable from 
measurement error. Alternatively, on a group level, 
group means would need to differ between 2.74 and 
3.58 (up to 4% of total score change) to ensure a true 
detection of a difference in people with stable symptoms. 
The standard error of measurement for the HIT-6 
was 2.42, resulting in a SDCindividual of 6.69 and 
SDCgroup of 0.78. When using the HIT-6 in individual 
assessment, changes in people with stable symptoms 
would need to exceed 6.7 points (16% of total score 
change) to be distinguishable from measurement error. 
Alternatively, on a group level, group means need to 
differ by 0.78 (up to 2% of total score change) to be 
distinguishable from measurement error in people with 
stable symptoms. 
Construct validity 
Most hypothesised associations were supported 
(Table 5): the CHQLQ’s three domains were strongly 
associated, with moderate to strong associations with 
the HIT-6. However, the association between role 
restriction and the SF-12 mental component score 
was stronger (moderate) than that observed with emo-
tional function, reflecting the emotional component of 
the role-restriction domain. (Appendix 3). Similarly, 
although smaller than hypothesised, associations 
between role restriction and the HADS were similar 
or greater than that observed for emotional function, 
reflecting the limited emotional content of the 
emotional-function domain specifically, and the 
CHQLQ generally. Moderate associations between 
the CHQLQ and the Social Impact Scale and Pain 
Self-Efficacy Scales reflect the CHQLQ focus on the 
social impact of headache and pain, respectively. 
A strong association with the Pain Self-Efficacy 
Questionnaire reflects the HIT-6 focus on pain. Apart 
from the moderate association with the Social Impact 
Scale, reflecting the HIT-6 emphasis on social impact, 
small associations with the remaining measures evidence 
a limited focus on the emotional impact of headache. 
Responsiveness (Table 6) 
Of the 105 people completing the 12-week question-
naire, 94 and 100 completed the health-transition ques-
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Table 6. Responsiveness of the CHQLQ and HIT-6 at 12 weeks. 
Headache-specific Difference SDC SDC 
health transitiona N Baseline 3-month (MIC)b SEMc individuald groupe ESf SRMg 
CHQLQ 
Role function – restriction (RR) 
Much better 10 70.50 (12.82) 90.00 (15.58) 19.50 (16.25) 11.49 31.85 10.07 1.521 1.2 
Better 19 65.89 (17.31) 76.68 (14.50) 10.79 (10.98) 7.766 21.526 4.94 0.623 0.982 
Same 53 62.94 (15.58) 69.98 (13.67) 7.04 (13.35) 9.44 26.167 3.59 0.452 0.527 
Worse 12 61.75 (22.76) 58.58 (11.43) 3.17 (14.35) 10.144 28.117 8.12 0.139 0.221 
Much worse 0 
Role function – prevention (RP) 
Much better 10 86.80 (10.36) 98.00 (3.89) 11.20 (11.26) 7.964 22.075 6.98 1.081 0.994 
Better 19 83.89 (12.41) 89.16 (11.47) 5.26 (7.86) 5.557 15.403 3.53 0.424 0.67 
Same 53 78.85 (14.65) 83.26 (13.86) 4.42 (12.71) 8.991 24.921 3.42 0.301 0.347 
Worse 12 68.08 (23.18) 67.33 (15.44) 0.75 (13.61) 9.621 26.667 7.7 0.032 0.055 
Much worse 0 
Emotional function (EF) 
Much better 10 69.30 (21.80) 88.70 (17.86) 19.40 (21.63) 15.294 42.393 13.41 0.89 0.897 
Better 19 68.74 (19.11) 76.74 (17.11) 8.00 (10.78) 7.623 21.13 4.85 0.419 0.742 
Same 53 66.32 (21.57) 68.89 (21.55) 2.57 (13.60) 9.618 26.66 3.66 0.119 0.189 
Worse 12 58.67 (24.06) 56.42 (24.91) 2.25 (14.59) 10.318 28.601 8.26 0.094 0.154 
Much worse 0 
HIT-6 
Much better 11 58.91 (8.31) 51.36 (8.32) 7.55 (5.18) 3.666 10.16 3.06 0.908 1.456 
Better 20 62.30 (5.19) 59.15 (4.93) 3.15 (4.86) 3.436 9.523 2.13 0.607 0.648 
Same 57 62.44 (6.49) 60.35 (6.59) 2.09 (5.03) 3.554 9.851 1.3 0.321 0.415 
Worse 12 64.33 (9.13) 64.75 (7.63) 0.42 (2.43) 1.718 4.761 1.37 0.046 0.172 
Much worse 0 
aHeadache-specific health transition – self-reported change in headache-specific health status at 12-weeks: Much better/better/same/worse/much 
worse. 
bMIC: Minimal important change – calculated as the mean change in those who have improved (better/much better) or deteriorated (worse). 
cSEM: Standard error of measurement. 
dSDCindividual represents the SDC in individuals and is calculated as: (SEM 1.96 2) (15,16). 
eSDCgroup represents the SDC in a group of individuals and is calculated as: (1.96 2 SEM n, where n is the group size) (3,15,16). 
fES: Effect size statistic – mean change in scores divided by the standard deviation of the baseline scores. 
gSRM: Standardised response mean – mean change in scores divided by the standard deviation of the change score. 
Smallest detectable change (SDC). The CHQLQ standard 
error of measurement ranged from 5.60 to 10.31 for 
participants indicating minimal improvement or dete-
rioration in headache status at 12 weeks. The resultant 
smallest detectable change for individuals 
(SDCindividual) for improvement ranged between 15 
(role prevention) to 21 (role restriction), and 26 (role 
restriction and role prevention) to 28 (emotional func-
tion) for deterioration. The corresponding smallest 
detectable change for groups (SDCgroup) ranged 
between 3 (role prevention) to 5 (role restriction) for 
improvement, and 7 (role prevention) to 8 (emotional 
function) for deterioration. These results imply that 
when using the CHQLQ for individual assessment, 
changes of <21 (improvement) or <28 (deterioration) 
points cannot be distinguished from error. However, 
much smaller differences are detectable for groups of 
patients: For groups who indicate minimal improve-
ment, a change from baseline to 12 weeks of >5 
points on the role-restriction and emotional-function 
domains and > 4 on the role-prevention domain are 
required to demonstrate a change that is greater than 
measurement error. For groups indicating minimal 
deterioration, a change of approximately 8 points is 
required to demonstrate change that is greater than 
measurement error. 
The standard error of measurement for the HIT-6 
ranged from 1.7 (deterioration) to 3.5 (improvement). 
The smallest detectable change at the individual level 
(SDCindividual) was 9.5 and 1.7, and at the group level 
(SDCgroup) was 2.1 and 1.3 for improvement and dete-
rioration, respectively. 
Minimal important change (MIC). Fifty-three of the 94 
valid CHQLQ responses at 12 weeks (56%) indicated 
no change in headache status (mean change in score 
between 2.57 (SD 13.6) (emotional function) and 7.04 
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(“better”) improvement, with a mean score improve-
ment (minimally important change) of 5.26 (role pre-
vention), 8.00 (emotional function) and 10.79 (role 
restriction). The remaining 12 participants reported a 
deterioration (“worse”) in headache status and a mean 
score deterioration of 0.75 (role prevention), 2.25 
(emotional function), and 3.17 (role restriction). The 
smallest difference between clinically stable and 
improved participants (i.e. the minimal clinically impor-
tant difference (MCID)) was 0.84 (role prevention), 3.75 
(role restriction) and 5.43 (emotional function). 
The minimally important change for the HIT-6 is 
3.15 and 0.42 for minimal improvement and deterio-
ration, respectively. The smallest difference between 
clinically stable and improved patients (minimal clini-
cally important difference) is 1.06 for the HIT-6. 
For both measures, the minimal important changes 
were greater than the smallest detectable change in 
groups (SDCgroup), indicating that a greater change in 
score is required to denote “important change” than 
that required to illustrate change that is greater than 
measurement error. 
Criterion-based responsiveness (Figure 1). Moderate corre-
lations between CHQLQ and HIT-6 change scores with 
the headache-specific transition item (range 0.35 
(emotional function) to 0.45 (role prevention); 0.36 
(HIT-6)), supported its use as an external marker of 
change (24). The higher AUC scores were found 
when dichotomising patients according to those who 
were “much better” versus those reporting that they 
were “better, the same or worse” (Figure 1). Two 
(role restriction, emotional function) CHQLQ domains 
exceeded 0.70 (lower bound 95% CI exceeding 0.50), 
indicating adequate responsiveness. However, the 
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Figure 1. ROC curves. 
Note: Respondents were dichotomised in three different ways: i) “Much better”: Headache was “much better” versus headache was 
better, about the same or worse; ii) “much better, better”: Headache was “much better” or “better” (that is, the improved group) 
versus headache was the same or worsened (the not improved group); and iii) “much better, better, same”: Headache had improved 
or remained about the same vs. headaches had deteriorated. 
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lower bound 95% CI of 0.53 (95% CI 0.53–0.84), sug-
gesting limited responsiveness. The AUC for the HIT-6 
exceeded 0.70 (95% CI 0.64–0.92). At this level of dis-
crimination, these results suggest adequate responsive-
ness. However, AUC less than 0.70 were found when 
participants were grouped differently (Figure 1). 
Effect size statistics. As hypothesised, both effect size and 
standardised response means for patient subgroups 
increased with increased reported improvement on 
the transition question. Moderate to large effect sizes 
were found for people reporting some (better) and 
greater (much better) improvements in headache 
status at 12 weeks for both the CHQLQ and HIT-6. 
However, for patients who were unchanged, most 
values (75%) did not confirm the hypothesis by exceed-
ing 0.2. Small numbers limited interpretation of any 
headache deterioration. 
Content validity 
We interviewed 14 participants (age 21–72 years; nine 
female) with chronic migraine. 
Typically, participants felt the CHQLQ was relevant 
to their headache experience, specifically welcoming the 
emotional impact items. However, item overlap – par-
ticularly around work – caused participants to refer 
back to previous items, and increased completion 
time. Participants described experiencing different 
headache intensities across the 4-week recall period, 
requiring judgement as to how they selected the most 
appropriate response. Double-barrelled items that 
aligned headache impact on “work” with “leisure 
activities” or “home” were challenging, as different 
environments influenced response. Contextual situa-
tions – for example, being retired or without depend-
ents – caused participants to rate headache impact 
differently. 
Typically, participants felt that the HIT-6 was rele-
vant, welcoming its brevity and simplicity. However, 
when considering different headache intensities, the 
lack of recall period (items 1 to 3) was problematic: A 
range of recall periods (daily, weekly, fortnightly, 
monthly, study duration) were reported to assist in 
completion. The lack of “pain severity” definition 
(item 1) was problematic – participants made their 
own judgement of severity before answering. The 
double-barrelled nature of three items (2, 5, and 6) 
caused concern. The impact of headache on work, 
social or household activities could be scored differently 
– some chose one activity, whereas others “averaged” 
activities. Ambiguity of meaning was raised for three 
items: item 3, “wishing” that one could lie down 
versus “actually” being able to lie down; item 4, what 
“tiredness” was, and its relationship to headache; and 
item 5, “fed up or irritated” was perceived as unclear. 
Discussion 
This comparative evaluation of the CHQLQ (adapted 
MSQ v2.1) and HIT-6 found the appropriateness of the 
CHQLQ as a measure of headache-specific quality of 
life was supported. Whilst the HIT-6 was similarly 
strong, concerns over content and relevance were 
identified. 
Although the shortness of the HIT-6 was welcomed, 
the capture of headache impact was limited when com-
pared to the CHQLQ. The CHQLQ questions address-
ing the emotional, symptomatic and social impact of 
headache were appreciated. However, item repetition 
and redundancy unnecessarily increased completion 
time. Participants “averaged” responses to manage 
the CHQLQ’s 4-week recall period; however, the lack 
of recall period for several HIT-6 items was a greater 
concern. This limitation was not identified by the quan-
titative analysis, highlighting the importance of seeking 
end-user perspectives throughout development and 
testing. Low levels of missing data supported the 
acceptability of both measures. 
The CHQLQ three-factor model was supported. 
However, the dual loading of item 12 (“fed-up or frus-
trated”) on both role-restriction and emotional-
function domains suggested multiplicity and interpre-
tation problems (25,28), which was further supported 
by a stronger item-total correlation with the role-
restriction domain than with the emotional-function 
domain. Qualitative interviews further identified 
CHQLQ item interplay between domains, describing 
the importance of context when thinking about head-
ache impact. Similar contextual problems, including a 
noticeable divide between work and social commit-
ments was described for both the CHQLQ and HIT-
6: For example, interviewees reported endeavouring to 
keep going while at work, but would often cancel social 
activities. 
The magnitude of the between-domain correlations 
found in our work suggest that the CHQLQ domains 
are measuring somewhat different aspects of headache-
related health and should be retained. Our confirmato-
ry factor analysis and work by Rendas-Baum et al. (26) 
further support this. High alpha values supported the 
internal consistency of the three CHQLQ domains. 
Similarly, high alpha values have been reported for 
the MSQv2.1 following completion by patients with 
chronic (27,28) and episodic migraine (8,27). 
The single-domain structure of the HIT-6 was sup-
ported by both factor analysis and high alpha values, 
confirming evidence following completion across 
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Low reliability was reported for the MSQv2.1 
(ICC < 0.70) in patients with “stable” episodic migraine 
at a 4-week retest (26). Acceptable levels have been 
reported for the HIT-6 (29,30). The high levels of reli-
ability in this study support application of both meas-
ures in groups, with the smallest detectable change 
(SDC) suggesting a CHQLQ difference in group 
means greater than 2.74 (role restriction), 2.86 (role 
prevention), 3.58 (emotional function) and 0.78 for 
the HIT-6 is required to demonstrate a real change in 
stable patients. 
Associations between different variables provided 
acceptable evidence of CHQLQ and HIT-6 construct 
validity, consistent with earlier MSQv2.1 (26,28) and 
HIT-6 (9,31) evaluations. However, the CHQLQ’s 
emotional function domain association with alternative 
measures of emotional wellbeing were less than hypoth-
esised. Given the importance afforded by patients to 
the emotional impact of headache, the inclusion of 
measures providing a more nuanced assessment of 
emotional wellbeing is recommended. 
Both measures demonstrated acceptable evidence of 
responsiveness to headache improvement over 12 
weeks. Moreover, two CHQLQ domains (role restric-
tion, emotional function) and the HIT-6 discriminated 
between dichotomous configurations of self-reported 
change in health when grouped as “much better” 
versus “better, same or worse”. The role-prevention 
domain was unable to discriminate at a higher level 
of discrimination. 
The minimal important change (MIC) values for 
both measures were greater than the smallest detectable 
change (SDC) for groups of patients whose headaches 
had minimally improved, indicating an “important 
change” for participants is greater than measurement 
error. The minimally important change values for 
CHQLQ domains closely approximate those reported 
following a 3-month completion of the MSQv2.1 by a 
large US-based, mixed population of migraineurs – 
role-restriction 5, role-prevention 5 to 7.9, emotional 
function 8.0 to 10.6 (32). 
The HIT-6 minimal important change value closely 
approximates that determined in US patients with 
chronic headache ( 3.7) (33) and Dutch patients with 
episodic migraine ( 2.5) (34). However, it is smaller 
than a minimal important change of 8.0 proposed in a 
Dutch study of patients with tension-type headache (35), 
where global improvement was defined according to 
both global improvement and a reduction in headache 
days (greater than 50%). Published minimal important 
change values for the HIT-6 range from 1.5 (episodic 
migraine) to 2.3 (chronic daily headache) (7,33–35), 
approximating the minimal clinical important difference 
(MCID) of 1.06 found in this study. 
This study describes the first, mixed methods com-
parative evaluation of two generic, headache-related 
quality of life measures that are not diagnosis specific, 
in a UK-based cohort of patients living with chronic 
headaches. Despite the importance of content validity 
to the relevance and acceptability of measures, few 
PROM-evaluative studies explore the qualitative 
aspects of measures (7). While both measures demon-
strated comparable psychometric properties, qualita-
tively the content validity of the CHQLQ was 
enhanced by the inclusion of items assessing the emo-
tional toll of chronic headache. However, all interviews 
were conducted with people with definite or probable 
chronic migraine, potentially limiting the generalisabil-
ity of these findings to other headache types. While the 
number of participants were adequate to support a 
robust evaluation of measurement data quality, reli-
ability and validity, the majority of participants 
reported “no change” in health at the 12-week 
follow-up, substantially reducing the numbers available 
to explore measurement responsiveness. Further evalu-
ations of measurement responsiveness in a larger 
cohort and following an active intervention will further 
enhance confidence in the measure’s ability to capture 
important change, and towards calculation of the min-
imal important change in score. Evidence suggests that 
the CHQLQ shows potential for further use in other 
groups of patients with chronic headache, but this anal-
ysis is limited to participants in a feasibility study (for a 
larger trial) (12). Hence, some caution is required in 
generalising conclusions and recommendations more 
widely to the general population of people with chronic 
headaches. 
Since the reported PROM evaluation was explicitly 
in people without a specific headache diagnosis, the 
evidence supports application of both measures in 
trials where recruitment takes place before diagnosis; 
for example, where diagnosis is part of the interven-
tion, or for epidemiologic surveys – for example, cap-
turing the impact of headache disorders. Further work 
may be needed to evaluate use of the CHQLQ in other 
populations of people with chronic headaches where 
case mix may be different. For example, it might be a 
useful measure for people with definite chronic 
migraine and medication overuse headache after fur-
ther evaluation in that population. That the design of 
this study did not allow a precise diagnosis for all par-
ticipants is not a weakness since the evaluation sought 
to provide evidence in support of the CHQLQ when 
assessing people with undiagnosed headache disorders. 
Conclusion 
This study describes the first comparative evaluation of 
the new CHQLQ with the HIT-6, demonstrating the 
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added value to be gained from a mixed-methods 
approach to PROM evaluation. The results of this 
study, and the consistency with previous evaluations, 
supports recommendation of the CHQLQ as a high 
quality, relevant and acceptable measure for chronic 
Clinical implications 
headache. In comparison to the HIT-6, for which sim-
ilarly strong psychometric evidence was reported, the 
CHQLQ had greater relevance to the wide-ranging 
impact of chronic headache. 
 The quality, relevance and acceptability of a new measure of chronic headache quality of life – the Chronic 
Headache Quality of Life Questionnaire (CHQLQ) – was compared with that of an existing measure, the 6-
item Headache Impact Text (HIT-6), following completion in a UK population. 
 The CHQLQ better captured the emotional, symptomatic and social impact of chronic headache. 
 Both measures had comparable measurement properties. 
 The CHQLQ is recommended as a high quality, relevant and acceptable measure for use with patients with 
chronic headache. 
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